Azd7762 clinical trial

National Library of Medicine U. National Institutes of Health U. Department of Health and Human Services. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Recruitment Status : Terminated Termination of the study was made after a full review of program data and assessment of the current risk-benefit profile. Drug: AZD Drug: gemcitabine. Phase 1. Study Type :. Interventional Clinical Trial.

Actual Enrollment :. Study Start Date :. Phase I solid tumors solid malignancies cancer Eligibility. National Library of Medicine U. National Institutes of Health U. Department of Health and Human Services. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Recruitment Status : Terminated Termination of the study was made after a full review of program data and assessment of the current risk-benefit profile.

Phase 1. Study Type :. Interventional Clinical Trial. Estimated Enrollment :. Study Start Date :. Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Inclusion Criteria: Histologically or cytologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective ECOG performance status of 0 or 1 Patient and tumor type must be suitable for treatment with weekly standard gemcitabine.

Exclusion Criteria: Inadequate bone marrow reserve, inadequate liver function or impaired renal function Any troponin elevation above normal range Stage II, III, or IV cardiac status, according to New York Heart Association NYHA classification; recent history ie, within 6 months of coronary artery disease or arteriosclerotic cardiovascular disease angina, myocardial infarction [MI] Any prior anthracycline treatment.

Contacts and Locations. Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials. More Information. Mixed solid tumors. National Library of Medicine U. National Institutes of Health U. The experiments herein employed mouse and human cell lines 11 , and gene expression was primarily examined using monolayer cell cultures.

Although clinical trials of AZD are not going forward due to unpredictable cardiac toxicity, inhibition of Chk remains an important therapeutic target Future work may aim to identify other Chk inhibitors that exhibit similar effects to AZD, and test their efficacy in a mouse model of bone metastasis. FEBS J. Cell Death Dis. Pharmacol Ther. View Article : Google Scholar. Toxicol Appl Pharmacol.

Int J Biol Macromol. Mol Cancer Ther. J Transl Med. J Mol Cell Biol. J Biol Chem. Int J Oncol. Hamamura K, Tanjung N and Yokota H: Suppression of osteoclastogenesis through phosphorylation of eukaryotic translation initiation factor 2 alpha. J Bone Miner Metab. J Bone Miner Res. Clin Exp Metastasis. Sci Rep. Tissue Eng Part B Rev. J Cell Biol. J Natl Cancer Inst. BMC Musculoskelet Disord.

Exp Cell Res. Int Endod J. Anal Biochem. Connect Tissue Res. Osteoarthritis Cartilage. Nat Rev Cancer. Cancer Chemother Pharmacol. September Volume 53 Issue 3. Sign up for eToc alerts. You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy. I agree. Home Submit Manuscript My Account. Advanced Search. Register Login.